ALKERMES | ALKS - Trade Creditors


ALKERMES reported $102.36M in Trade Creditors for its fiscal quarter ending in March of 2026.





Trade Creditors Change Date
AbbVie USD 3.59B 28.65B Dec/2025
Acadia Pharmaceuticals USD 12.25M 1.34M Mar/2026
ALKERMES USD 102.36M 5.59M Mar/2026
Amgen USD 19.52B 1.37B Mar/2026
Biogen USD 358.5M 73.5M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Bristol-Myers Squibb USD 4.23B 659M Mar/2026
Coherus Biosciences USD 9.91M 14.98M Dec/2025
Eli Lilly USD 5.03B 350M Mar/2026
Gilead Sciences USD 645M 70M Mar/2026
Heron Therapeutics USD 8.97M 24K Mar/2026
Ionis Pharmaceuticals USD 26.03M 2.05M Mar/2026
J&J USD 10.46B 1.53B Mar/2026
Malin Corporation EUR 700K 200K Dec/2024
Merck USD 3.86B 541M Mar/2026
Minerva Neurosciences USD 640K 305K Dec/2025
Nektar Therapeutics USD 10.77M 4.79M Dec/2025
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Otsuka Holdings JPY 196.04B 29.53B Mar/2026
Ovoca Bio EUR 186K 23K Jun/2025
Pfizer USD 4.51B 734M Mar/2026
Regeneron Pharmaceuticals USD 1.03B 4.81B Mar/2026
Vertex Pharmaceuticals USD 3.47B 40.6M Mar/2026